Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2004 1
2005 1
2008 1
2009 2
2010 3
2011 3
2013 1
2014 1
2017 4
2018 2
2019 2
2020 2
2021 1
2022 7
2023 4
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Global multi-stakeholder endorsement of the MAFLD definition.
Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Korenjak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Méndez-Sánchez N, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. Lancet Gastroenterol Hepatol. 2022. PMID: 35248211 Free article. No abstract available.
Global multi-societies endorsement of the MAFLD definition.
Alboraie M, Tanwandee T, Xu X, Nikolova D, Estupiñan EC, Ghazinyan H, Alawadhi S, Ocama P, Aghayeva G, Piscoya A, Farahat T, Prasad P, Lesmana CRA, Joshi SR, Al-Busafi S, Milivojevic V, Kayamba V, Lee YY, Alam S, Tang C, Xie WF, Derbala M, Nan Y, Ndububa D, Zheng H, Zhao J, Alkhalidi N, Ghanem Y, Charatcharoenwitthaya P, Mahtab M, Hegazy NN, Sinkala E, Dovia CK, Mahamat MA, El-Shabrawi M, Hang DV, Vinker S, Hotayt B, Tahiri M, Bogomolov P, Afredj N, Shaltout I, Elwakil R, Hamed AE, Kamani L, Abdulla M, Assi C, Baatarkhuu O, Tarrah MA, Ajlouni Y, Abidine B, Muñoz C, Ali M, Salama E, Elamin A, Memon IA, Mirijanyan A, Jamil S, Nersesov AV, Ekanem N, Hamoudi W, Bright B, Casanovas T, Itodo E, Torres EA, Karin M, Zerem E, Turcan S, Dulskas A, Lupasco I, Jucov A, Tzeuton C, Sombie R, Lapshyna K, Dorofeyev A, Awuku YA, Duda HÜ, Ande R, Koofy NE, Kamal N, Pan Z, Peltec A, Qiao L, Rakotozafindrabe ALR, Salama A, Soliman R, Wafaa B, Debu M, Micah EA, Shiha G, Eslam M, Fouad Y. Alboraie M, et al. Among authors: dorofeyev a. Ann Hepatol. 2024 Nov-Dec;29(6):101573. doi: 10.1016/j.aohep.2024.101573. Ann Hepatol. 2024. PMID: 39477629 Free article. No abstract available.
Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Dignass A, Stremmel W, Horyński M, Poyda O, Armerding P, Fellermann K, Langhorst J, Kuehbacher T, Uebel P, Stein J, Novacek G, Avalueva E, Oliinyk O, Hasselblatt P, Dorofeyev A, Heinemann H, Mueller R, Greinwald R, Reinisch W; International PROTECT-1/2 Study Groups. Dignass A, et al. Among authors: dorofeyev a. Clin Gastroenterol Hepatol. 2024 Apr;22(4):810-820.e7. doi: 10.1016/j.cgh.2023.09.031. Epub 2023 Oct 6. Clin Gastroenterol Hepatol. 2024. PMID: 37806372 Free article. Clinical Trial.
Efficacy and safety of fecal microbiota transplantation via colonoscopy as add-on therapy in patients with mild-to-moderate ulcerative colitis: A randomized clinical trial.
Tkach S, Dorofeyev A, Kuzenko I, Falalyeyeva T, Tsyryuk O, Kovalchuk O, Kobyliak N, Abenavoli L, Boccuto L. Tkach S, et al. Among authors: dorofeyev a. Front Med (Lausanne). 2023 Jan 12;9:1049849. doi: 10.3389/fmed.2022.1049849. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36714101 Free PMC article.
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Kruis W, Siegmund B, Lesniakowski K, Simanenkov V, Khimion L, Sobon M, Delmans G, Maksyashina SV, Sablin OA, Pokrotnieks J, Mostovoy Y, Datsenko O, Abdulkhakov S, Dorofeyev A, Levchenko O, Alexeeva O, Andreev P, Kolesnik IP, Mihaly E, Abrahamovych O, Baluta M, Kharchenko N, Viacheslav N, Uspenskiy Y, Vieth M, Mohrbacher R, Mueller R, Greinwald R. Kruis W, et al. Among authors: dorofeyev a. J Crohns Colitis. 2022 Nov 23;16(11):1714-1724. doi: 10.1093/ecco-jcc/jjac081. J Crohns Colitis. 2022. PMID: 35709376 Free PMC article. Clinical Trial.
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus T, Kocjan A, Müser M, Baranovsky A, Mikhailova TL, Zvyagintseva TD, Dorofeyev AE, Lozynskyy YS, Cascorbi I, Stolte M, Vieth M, Dilger K, Mohrbacher R, Greinwald R; International Salofalk Suppository OD Study Group. Andus T, et al. Among authors: dorofeyev ae. Inflamm Bowel Dis. 2010 Nov;16(11):1947-56. doi: 10.1002/ibd.21258. Inflamm Bowel Dis. 2010. PMID: 20310020 Clinical Trial.
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Kruis W, Jonaitis L, Pokrotnieks J, Mikhailova TL, Horynski M, Bátovský M, Lozynsky YS, Zakharash Y, Rácz I, Kull K, Vcev A, Faszczyk M, Dilger K, Greinwald R, Mueller R; International Salofalk OD Study Group. Kruis W, et al. Aliment Pharmacol Ther. 2011 Feb;33(3):313-22. doi: 10.1111/j.1365-2036.2010.04537.x. Epub 2010 Dec 8. Aliment Pharmacol Ther. 2011. PMID: 21138455 Clinical Trial.
30 results